布地奈德/福莫特罗在慢性阻塞性肺疾病稳定期中的疗效分析被引量：3

导出

摘要目的探讨布地奈德/福莫特罗在慢性阻塞性肺疾病稳定期中的临床治疗效果。方法选取2014年10月至2015年10月我院诊治的126例中重度慢性阻塞性肺疾病稳定期患者资料进行分析,采用随机对照方法将患者分为对照组和实验组,对照组采用口服茶碱类制剂茶碱缓释片并吸入特布他林气雾剂治疗,实验组采用布地奈德/福莫特罗吸入治疗,比较两组临床疗效。结果实验组加重次数,显著少于对照组(P<0.05);实验组发作时间间隔,显著长于对照组(P<0.05);两组患者治疗前呼吸困难评分、生活质量评分差异不显著(P>0.05);实验组治疗后呼吸困难及生活质量评分,显著低于对照组(P<0.05)。结论慢性阻塞性肺疾病稳定期患者中采用布地奈德/福莫特罗吸入治疗效果理想,值得推广应用。

作者李献荣

机构地区云南省文山州中医医院肺病科

出处《中国医药指南》 2016年第9期124-125,共2页 Guide of China Medicine

关键词布地奈德福莫特罗慢性阻塞性肺疾病

分类号 R563.8 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献5

1何静春,高静珍,刘淑芹,邢爱民.布地奈德／福莫特罗联合噻托溴铵吸入治疗C、D级慢性阻塞性肺疾病患者效果观察[J].中国综合临床,2012,28(7):715-717. 被引量：7
2廖军红,黄兰卿,李伟棠,梁红卫,邓睿,钟英豪,张志萍,李世泽.噻托溴铵联合微波治疗慢性阻塞性肺疾病稳定期患者的效果观察[J].中国综合临床,2015,31(8). 被引量：6
3魏亚强,赵红.布地奈德/福莫特罗粉剂联合噻托溴铵粉剂吸入治疗稳定期慢性阻塞性肺疾病临床研究[J].陕西医学杂志,2012,41(7):880-881. 被引量：36
4黄怀焕,林俊锋.噻托溴铵加用布地奈德福莫特罗粉吸入剂联合无创通气治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的效果[J].中国医药导报,2015,12(5):91-94. 被引量：81
5杨泽辉,陈晓东,张强.慢性阻塞性肺疾病和支气管哮喘吸入布地奈德／福莫特罗的肺功能时间变化趋势研究[J].中国基层医药,2014,21(9):1360-1361. 被引量：6

二级参考文献26

1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量：8243
2Rana GS, York TP, Edmiston JS, et al. Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD) [ J ]. Anal Bioanal Chem,2010,397 (5) : 1809-1819.
3Worth H, FSrster K, Eriksson G, et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD [ J ]. Respir Med ,2010,104 (10) : 1450-1459.
4Brashier B, Dhembare P, Jantikar A, et al. Tiotropium administered by a.pressurized metered dose inhaler (pMDI) and spacer produces a similar bronehodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD [ J ]. Respir Med,2007,101 (12) :2464-2471.
5Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary [J]. Am J Respir Crit Care Med, 2001,163:1256 - 76.
6Jone PW, Quirk FH ,Baveystock CM , et al . The ST Georg's Respiratory Questionnaire [J]. Respir Med, 1991 ,85 (SupplB) :25.
7Cazzola M, Donner CF. Long-acting β2-agonists in the management of stable chronic obstructive pulmonary dis- ease[J]. Drugs, 2000, 60:307 - 320.
8Cazzola M, Dahl R. Inhaled combination therapy" with longacting 132-agonists and corticosteroids in stable COPD[J]. Chest, 2004, 126:220 - 37.
9Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and flutieasone propionate and survival in chronic ob- structive pulmonary disease[J]. N Engl J Med, 2007, 356:775-89.
10Tashkin DP, Celli B, Senn S. A 4-year trial of tiotropi- um in chronic obstructive pulmonary disease[J]. N Engl J Med, 2008, 359:1543 - 1554.